Protagonist Therapeutics, Inc (PTGX) is a publicly traded Healthcare sector company. As of May 20, 2026, PTGX trades at $100.71 with a market cap of $6.48B and a P/E ratio of -55.44. PTGX moved +2.53% today. Year to date, PTGX is +19.84%; over the trailing twelve months it is +116.43%. Its 52-week range spans $33.31 to $107.84. Analyst consensus is strong buy with an average price target of $117.00. Rallies surfaces PTGX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Protagonist Therapeutics, Inc (PTGX) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. PTGX moved +2.53% today. Analyst consensus is strong buy.
| Metric | Value |
|---|---|
| Price | $100.71 |
| Market Cap | $6.48B |
| P/E Ratio | -55.44 |
| EPS | $-1.81 |
| Dividend Yield | 0.00% |
| 52-Week High | $107.84 |
| 52-Week Low | $33.31 |
| Volume | 295.34K |
| Avg Volume | 0 |
| Revenue (TTM) | $74.06M |
| Net Income | $-114.71M |
| Gross Margin | 0.00% |
11 analysts cover PTGX: 0 strong buy, 10 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $117.00.